Is Aceminid a Medicare drug?

Asciminib (Asciminib), as a new type of targeted treatment drug for chronic myeloid leukemia (CML), has not yet been officially launched in mainland China, and therefore has not yet been included in China's medical insurance directory. Since the drug cannot be purchased through formal channels in China, patients can only rely on overseas purchase channels to obtain Asiminib.

In foreign markets, there are two main sources of Aceminid: original drugs and generic drugs. Original drugs mainly come from Europe, and their prices are relatively high, usually around tens of thousands of yuan. This price burden is high for most patients, especially those who require long-term medication. The high price of brand-name drugs has led many patients to seek more affordable generic drugs.

Laos is one of the major producers of generic drugs of Aceminid. The price of generic drugs in Laos is about more than 4,000 yuan, which is much cheaper than the original drugs. Although the price of generic drugs is lower, their pharmaceutical ingredients are basically the same as the original drugs, and they can also achieve similar therapeutic effects. Therefore, many patients choose Lao generic drugs as alternatives to reduce their financial burden.

At present, Acemini has not yet entered the Chinese market and is not included in the scope of medical insurance, so patients cannot reimburse related expenses through medical insurance. For many patients with chronic myelogenous leukemia who require long-term treatment, this means they are responsible for the entire cost of their medications. If Acemini is launched in China and entered into the medical insurance directory in the future, patients' financial pressure may be significantly reduced. At the same time, the emergence of generic drugs has given patients more choices, allowing them to obtain effective treatments at lower costs.

Acemini is not yet on the market in China, and patients can only purchase it through overseas channels, and it is not currently included in the domestic medical insurance system. In terms of price, original drugs are expensive, while generic drugs provide a more economical option.